Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.2 - $2.08 $640 - $6,656
-3,200 Reduced 1.55%
203,600 $41,000
Q2 2023

Aug 11, 2023

BUY
$2.0 - $3.2 $413,600 - $661,760
206,800 New
206,800 $426,000
Q4 2022

Feb 13, 2023

SELL
$1.37 - $4.42 $60,143 - $194,038
-43,900 Reduced 78.82%
11,800 $19,000
Q3 2022

Nov 14, 2022

BUY
$2.55 - $4.42 $98,430 - $170,612
38,600 Added 225.73%
55,700 $246,000
Q2 2022

Aug 12, 2022

BUY
$2.71 - $3.6 $46,341 - $61,560
17,100 New
17,100 $47,000
Q3 2021

Nov 12, 2021

SELL
$3.14 - $4.09 $149,464 - $194,684
-47,600 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$3.01 - $4.01 $143,276 - $190,876
47,600 New
47,600 $181,000
Q1 2021

May 13, 2021

SELL
$3.46 - $7.88 $94,804 - $215,912
-27,400 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$3.99 - $17.73 $109,326 - $485,802
27,400 New
27,400 $124,000
Q3 2020

Nov 13, 2020

SELL
$11.19 - $16.92 $1.58 Million - $2.39 Million
-141,238 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$4.42 - $12.66 $1.92 Million - $5.51 Million
-435,400 Reduced 75.51%
141,238 $1.58 Million
Q1 2020

May 14, 2020

BUY
$4.01 - $8.88 $973,251 - $2.16 Million
242,706 Added 72.68%
576,638 $2.68 Million
Q4 2019

Feb 13, 2020

BUY
$3.62 - $4.29 $133,194 - $157,846
36,794 Added 12.38%
333,932 $1.43 Million
Q3 2019

Nov 13, 2019

BUY
$3.54 - $4.48 $257,573 - $325,969
72,761 Added 32.43%
297,138 $1.16 Million
Q2 2019

Aug 12, 2019

BUY
$3.59 - $4.3 $77,974 - $93,396
21,720 Added 10.72%
224,377 $886,000
Q1 2019

May 14, 2019

BUY
$3.37 - $4.34 $68,074 - $87,668
20,200 Added 11.07%
202,657 $880,000
Q4 2018

Feb 13, 2019

BUY
$2.98 - $3.9 $543,721 - $711,582
182,457 New
182,457 $648,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $69.3M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.